LGALS1 and glioblastoma: In this context, CS-lipid NPs were designed to deliver anti-galectin-1 and anti-epidermal growth factor receptors-siRNAs in glioblastoma treatment because galectin-1 and EGFR are overexpressed in glioblastoma cells and are associated with the proliferation and invasion of cancer cells.